Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Analysis from the Acute Coronary Syndrome Israeli Survey.
Acute coronary syndrome
Percutaneous coronary intervention
Prasugrel
Ticagrelor
Journal
Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
08
2021
accepted:
16
11
2021
pubmed:
23
11
2021
medline:
8
4
2022
entrez:
22
11
2021
Statut:
ppublish
Résumé
We aimed to compare the outcomes of acute coronary syndrome (ACS) patients undergoing in-hospital percutaneous coronary intervention treated with prasugrel versus ticagrelor. Among 7,233 patients enrolled to the Acute Coronary Syndrome Israeli Survey (ACSIS) between 2010 and 2018, we identified 1,126 eligible patients treated with prasugrel and 817 with ticagrelor. Comparison between the groups was performed separately in ST-elevation myocardial infarction (STEMI) patients, propensity score matched (PSM) STEMI patients, and non-ST-elevation ACS (NSTE-ACS) patients. In-hospital complication rates, including rates of stent thrombosis, were not significantly different between groups. In PSM STEMI patients, 30-day re-hospitalization rate (p < 0.05), 30-day MACE (the composite of death, MI, stroke, and urgent revascularization, p = 0.006), and 1-year mortality rates (p = 0.08) were higher in the ticagrelor group compared to the prasugrel group; in NSTE-ACS patients, outcomes were not associated with drug choice. In Cox regression analysis applied on the entire cohort, prasugrel was associated with lower 1-year mortality in STEMI patients but not in NSTE-ACS patients (p for interaction 0.03). Compared to ticagrelor, prasugrel was associated with superior clinical outcomes in STEMI patients, but not in NSTE-ACS patients.
Identifiants
pubmed: 34808635
pii: 000521042
doi: 10.1159/000521042
pmc: PMC9153328
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Prasugrel Hydrochloride
G89JQ59I13
Ticagrelor
GLH0314RVC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-120Informations de copyright
© 2021 The Author(s). Published by S. Karger AG, Basel.
Références
Circulation. 2020 Jul 14;142(2):150-160
pubmed: 32468837
Circulation. 2020 Dec 15;142(24):2329-2337
pubmed: 33115278
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
N Engl J Med. 2012 Oct 4;367(14):1297-309
pubmed: 22920930
JACC Cardiovasc Interv. 2017 Aug 28;10(16):1646-1658
pubmed: 28838475
J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140
pubmed: 23256914
Open Heart. 2019 Jun 29;6(1):e000951
pubmed: 31328001
J Am Heart Assoc. 2020 Mar 3;9(5):e014411
pubmed: 32122216
N Engl J Med. 2007 Nov 15;357(20):2001-15
pubmed: 17982182
Heart. 2018 Oct;104(20):1683-1690
pubmed: 29437885
J Am Coll Cardiol. 2020 Nov 24;76(21):2436-2446
pubmed: 33213722
Am J Cardiovasc Drugs. 2019 Aug;19(4):381-391
pubmed: 31030413
Eur Heart J. 2020 Sep 1;41(33):3144-3152
pubmed: 31899473
Heart. 2021 Jul;107(14):1145-1151
pubmed: 33712510
N Engl J Med. 2013 Sep 12;369(11):999-1010
pubmed: 23991622
J Am Coll Cardiol. 2020 Nov 24;76(21):2569-2571
pubmed: 33213734
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Eur Heart J Cardiovasc Pharmacother. 2021 Mar 15;7(2):94-103
pubmed: 31965164
J Am Coll Cardiol. 2018 Jan 30;71(4):371-381
pubmed: 29154813
Circ J. 2018 Jun 25;82(7):1866-1873
pubmed: 29643279